Developing storyline

Moderna's melanoma vaccine trial success fuels stock rally

Positive Phase 3 data for Merck and Moderna's personalized mRNA melanoma vaccine boosts Moderna's stock, helping lift the broader U.S. healthcare sector and Wall Street.

2 stories237 sourcesUpdated Aug 20, 2026

In this storyline:Moderna Merck & Co.pembrolizumab Federal Reserve System United States Department of the Treasury

Coverage momentum

total articles across this storyline · last 72h

Key developments

Aug 19, 2026
Merck and Moderna report positive Phase 3 results for their personalized mRNA melanoma vaccine added to Keytruda, showing longer recurrence-free survival and no new safety issues.
245 sources on this →
Aug 19, 2026
Moderna's stock rallies sharply on the trial news, lifting the healthcare sector and helping push U.S. stocks higher as Treasury yields ease.
5 sources on this →

Coverage across the spectrum

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Stories in this storyline

Photo: Fletcher / Wikimedia Commons (CC BY 4.0)

Health

Merck, Moderna Positive Phase 3 Melanoma Vaccine

Merck and Moderna reported positive Phase 3 results for their personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) added to Keytruda in high-risk, surgically treated melanoma, showing longer recurrence-free survival and reduced distant metastasis with no new safety issues. The companies plan regulatory discussions and potential accelerated approval submissions, with data presentations at upcoming medical meetings and continued follow-up for overall survival.

245 sources

Photo: Photographer: Airman 1st Class Anna Nolte Post-production: Zacharie Grossen / Wikimedia Commons (Public domain)

Comments

Ask this storyline anything:

Free account · your comment posts right after signup

Finance

Wall Street rises as yields ease, Moderna lifts healthcare stocks

U.S. stocks rose modestly as easing government yields supported risk appetite, with Moderna’s strong rally boosting the healthcare sector and lifting major indexes. Investors weighed Fed minutes signaling potential rate hikes against Treasury moves to expand liquidity supports, keeping a wary view on longer-term rate trajectories for tech and other high-flyers.

5 sources